Mosunetuzumab news

All news on Mosunetuzumab (also known as Lunsumio): plants, production capacities, investments and involved companies in Europe.

19 September 2025
Roche's Lunsumio Subcutaneous Formulation Recommended for EU Approval
Lunsumio SC offers faster administration and high response rates for relapsed follicular lymphoma, with low cytokine release syndrome risk, pending EU approval.

Who will be producing Mosunetuzumab in the future?

Find out with chemXplore Analytics